Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
LiQO OLI is an oral dietary supplement developed and manufactured by Abian Pharmed. It contains medium-chain triglycerides (MCT oil) derived from coconut and palm kernel oils. MCTs are rapidly absorbed and metabolized by the liver, providing an immediate source of energy. LiQO OLI is indicated for the dietary management of individuals with fat malabsorption disorders, malnutrition, chronic liver disease, cystic fibrosis, or those requiring a ketogenic diet (such as patients with drug-resistant epilepsy). It is also utilized by athletes to enhance energy and endurance, and to support weight management.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on medium-chain triglycerides.